You are here: Industry Insights > Alzheimer's Disease

News List

AlzProtect, on Track for a Phase 2 Entry in 2019, for its Drug Candidate AZP2006 b3cnewswire
February 21, 2019
AlzProtect, a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer's disease and Progressive Supranuclear Palsy (PSP)....
FDA takes action against 17 companies for illegally selling products claiming to treat Alzheimer's disease worldpharmanews
February 12, 2019
The U.S. Food and Drug Administration (FDA) today posted 12 warning letters and 5 online advisory letters issued to foreign and domestic companies that are illegally selling more than 58 products...
Scientists pave the way for saliva test for Alzheimer's disease worldpharmanews
December 13, 2018
University of Alberta scientists have identified three biomarkers for detecting mild cognitive impairment and Alzheimer's disease in saliva samples. The research has promising results for application in a clinical setting.
Eisai announces Data from the Phase II Clinical Trial of BAN2401 biospectrumasia
October 29, 2018
Clinical Study 201 is a placebo-controlled, double-blind, parallel-group, randomized study in 856 patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) with confirmed amyloid pathology in the brain
XingImaging announces Alzheimer's disease PET imaging in China biospectrumasia
September 04, 2018
XingImaging also anticipates expanding their current production network from five sites in 2018 to 10 sites in 2019
Breakthrough! Phase III Clinical Study of the Chinese New Drug for Alzheimer's Disease Met the Endpoint and is Waiting for Marketing Muzi
August 02, 2018
This can be called a “cardiac stimulant” to the AD drug market that has long been sluggish.
Biogen’s Alzheimer’s drug succeeds in trial biospectrumasia
July 09, 2018
The study achieved statistical significance on key predefined endpoints evaluating efficacy at 18 months on slowing progression in Alzheimer's Disease Composite Score (ADCOMS) and on reduction of amyloid accumulated in the brain as measured using amyloid-
Update on Phase III clinical trials of lanabecestat for Alzheimer's disease worldpharmanews
June 20, 2018
AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor
Boehringer Ingelheim Refocuses PDE9 Inhibition Brain Research on Schizophrenia americanpharmaceuticalreview
February 12, 2018
These AD trials were part of an extensive clinical trial program exploring the efficacy of compounds which target malfunctioning of specific (glutamatergic) brain circuits as potential new treatments for specific symptoms and traits of mental illness.
Study:Blood Pressure Fluctuations linked to Alzheimer's Risk drugs.com
August 08, 2017
If your blood pressure varies from day-to-day, you may be at higher risk for dementia or Alzheimer's disease, new research from Japan suggests.

Previous page 1 2 3 4 Next page